Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
E. R. Squibb & Sons L.L.C.;Ono Pharmaceutical Co Ltd
发明人:
Srinivasan, Mohan,Cardarelli, Josephine M,Huang, Haichun,Selby, Mark J,Chen, Bingliang,Korman, Alan
申请号：
NO20170138
公开号：
NO344818B1
申请日:
2017.01.30
申请国别(地区):
NO
年份:
2020
代理人:
摘要：
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
